

St George Hospital Renal Department: INTERNAL ONLY

Iron supplementation for home haemodialysis patients

[Ferritin < 200 ng/ml and TSAT < 20%]

During Home Training:

- As per ward protocol

When patient at home:

- Need for iron infusion is monitored by the Nephrologist
- Patient will self administer as per training or contact Sydney Dialysis Centre (SDC) for assistance
- Patient can attend Home Training for assistance if unsure of method

Indications for intravenous iron infusion:

- Intolerance to oral iron
- Iron deficiency or suboptimal response to ESA therapy despite oral iron supplementation

Intravenous iron infusion:

- Instructions for IV iron infusion given during home training or by SDC

Recommended dosage schedule:

- IV iron 100 mg each dialysis session for 10 consecutive sessions unless contraindicated
- Check Fe studies 1 month after completion of course or when bloods next due
- Once optimal iron parameters are achieved, titrate IV iron to monthly dose or as per Nephrologist

Initial infusion:

- Given during home training session or under supervision by SDC
- Dilute 100 mg IV iron in 100 mls 0.9% normal saline and infuse via an infusion control device at a rate of 15 mls/hr for the first 30 minutes (program pump for rate 15 mls/hr and volume 7.5 mls)
- In the absence of a reaction, increase pump speed to 120 mls/hr

Subsequent infusions:

- Call SDC or Home Training Nurse for assistance if unsure of method
- Draw up 100 mg IV iron into a 20 ml syringe and dilute to a volume of 20 mls with 0.9% normal saline
- Turn down blood flow rate to 200 ml per minute
- Swab arterial port and administer as a bolus slowly over 2 – 5 minutes towards the end of dialysis

References:

1. McMahon L. Haemoglobin. *Nephrology*. 2008; 13:s44-s47
2. CARI: Caring for australians with renal impairment: Guideline summary; 2009 [cited 2010 July 14]. Available from: http://www.cari.org.au/DIALYSIS_bht_published/Iron.pdf
3. Macdougall I, Eckardt K. Chapter 72: Anaemia in chronic kidney disease. In Feehally J, Floege J, Johnson R J. *Comprehensive clinical nephrology*. 3rd ed. Philadelphia: Mosby, 2007. p. 853-860
4. Singh A K, Hertello P. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease. *Nephrol Nurs J*. 2005; 32(2):199-206
5. Goldsmith D, Covic A. Time to reconsider evidence for anaemia treatment (TREAT) = Essential safety arguments (ESA). *Nephrol Dial Transplant*. 2010; 25:1734-1737
6. FDA Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA): FDA ALERT [11/16/2006, Updated 2/16/2007 and 3/09/2007]. Available: <http://www.fda.gov.au>
7. Unger E F, Thompson A M, Blank M J, Temple R. Erythropoiesis-stimulating agents – Time for a reevaluation; 2010 [cited 2010 January 1]. Available from: www.nejm.org
8. Anker S D, Toto R. Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. *NDT Plus*. 2009; 2(Suppl 1):i3-i8
9. Eason A. Correcting iron-restricted erythropoiesis and improving anemia in patients on hemodialysis: practical tips that can make a difference. *Nephrol Nurs J*. 2009; 36(5):529-534
10. De Francisco A L M, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. *NDT Plus*. 2009; 2(Suppl 1):i18-i26
11. Burrows LaV, Muller R. Chronic kidney disease and cardiovascular disease: pathophysiologic links. *Nephrol Nurs J*. 2007; 34(1):55-63
12. Daugirdas J T, Blake P G, Ing T S. *Handbook of dialysis*. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 159-162, 477-489
13. KDOQI (Kidney Disease Outcomes Quality Initiative). Clinical practice recommendation for anaemia in chronic kidney disease in adults. 2006 [cited 2009 September 15]. Available from: <file:///F:/Anaemia%20identifying%20patients.htm>
14. Enders H M. Evaluating iron status in hemodialysis patients. *Nephrol Nurs J*. 2002; 29(4):366–369
15. Strippoli G F M, Navaneethan S D, Craig J C, Palmer S C. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. *Cochrane database of*

systematic reviews. 2006, Issue 4 [cited 2010 May 5]. Available from:
<http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles>

16. Hayat A, Haria D, Salifu M. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. *Patient Prefer Adherence*. 2008; 2:195-200
17. Locatelli F, Covic A, Eckardt E-U, Wiecek A, Vanholder R. Anaemia management in patients in chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). *Nephrol Dial Transplant*. 2009; 24:348-354